CD8A and colorectal cancer: Accordingly, it has been postulated that treatment of colorectal cancer in a murine model with oxaliplatin in combination with IL-12 resulted in the eradication of metastatic colorectal tumors and inhibition of tumor recurrence as well as enhancing the ratio of CD8+ T lymphocyte/myeloid-derived suppressor cells (MDSCs) and CD8+ T lymphocyte/Tregs within the tumors [251].